EUVIMEDEUVIMED entdecken
Open Access

Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients?

Misbah Nizamani

Sarcoidosis vasculitis and diffuse lung diseases · 10.12.2024 · 41 (4) · e2024036-e2024036

DOI: 10.36141/svdld.v41i4.15873 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 10.12.2024. Verfasst von Misbah Nizamani. Beteiligte Einrichtung: Dow Medical College, DUHS. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sarcoidosis is a multi-system disorder characterized by the formation of non-caseating granulomas. It is a disorder of unknown etiology. Interferon-induced sarcoidosis is a well-known phenomenon. However, in the past few years, few cases have come forward in which after treatment with a monoclonal antibody, Alemtuzumab, patients developed sarcoidosis. This antibody targets the pan-lymphocyte CD52 antigen found on both human lymphoid and myeloid cells and is used in the treatment of Relapsing Remitting Multiple Sclerosis, leukemia, etc. Patients, in these cases, after a few years of treatment developed sarcoidosis but fortunately responded well to the treatment, if needed.

Schlagwörter

sarcoidosisalemtuzumabdrug-induced sarcoidosisCD52monoclonal antibody adverse effectsnon-caseating granulomasrelapsing-remitting multiple sclerosis

Autor:innen und Institutionen

  • Dow Medical College, DUHS.

Zitieren

APA

Nizamani, M. (2024). Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients?. Sarcoidosis vasculitis and diffuse lung diseases, 41(4), e2024036-e2024036. https://doi.org/10.36141/svdld.v41i4.15873

Vancouver

Nizamani M. Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients?. Sarcoidosis vasculitis and diffuse lung diseases. 2024;41(4):e2024036-e2024036. doi:10.36141/svdld.v41i4.15873

BibTeX
@article{Nizamani2024,
  author = {Nizamani, Misbah},
  title = {Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients?},
  journal = {Sarcoidosis vasculitis and diffuse lung diseases},
  year = {2024},
  volume = {41},
  number = {4},
  pages = {e2024036--e2024036},
  doi = {10.36141/svdld.v41i4.15873}
}
Kostenlos starten →